Developer docs
API playgroundTry for free, no card

Search company profiles

Pre Diagnostics

Full company profile

uuid00042y3

Namestring
Pre Diagnostics
Legal namestring
Pre Diagnostics AS
Company typeenum
Private
Founded yearint
2013
Descriptiontext

Pre Diagnostics AS is a privately held Norwegian diagnostic company founded in 2013 in Oslo, developing biomarker-based blood tests for early detection and management of neurodegenerative diseases, primarily Alzheimer's and Parkinson's. The company's core technology is a proprietary two-step platform that measures beta-amyloid (Aβ) clearance efficiency inside blood monocytes using positive isolation with paramagnetic beads followed by proprietary monoclonal antibody detection of specific Aβ cut-point fragments (aa-34, 20-aa, aa-40/42). Its lead commercial product, PreADx, is the first CE-marked in-vitro diagnostic blood test using intracellular peptide quantitation for early Alzheimer's disease detection, and it has also CE-marked the Plasma Aβx-34 biomarker for monitoring Amyloid-Related Imaging Abnormalities (ARIA) during anti-amyloid immunotherapy, with BloodCellDx-AD in development for ARIA risk prediction.

Pre Diagnostics operates three revenue streams: (i) professional biomarker services through its wholly owned subsidiary Pre Neurolab, a service laboratory established in 2022 and expanded in February 2026 with MSD and Kleeya immunoassay platforms supporting studies from 50 to several thousand samples; (ii) licensing and royalty arrangements under active dialogue with pharmaceutical companies for clinical research, patient monitoring, and diagnostic applications; and (iii) one-time license sales of CE-marked diagnostic tests. The company sells primarily to pharmaceutical companies conducting neurodegenerative clinical trials and to academic research institutions and hospitals, with secondary outreach to clinicians via the PreADx test. The commercial footprint is currently European, anchored by participation in the €7.7 million Horizon Europe-funded FluiDx-AD consortium led by Oslo University Hospital, alongside the Norwegian Research Council-funded Parkinson's program. The company is small (1-10 employees), ISO 13485 certified, and has historically been financed primarily through EU and Norwegian research grants rather than commercial revenue.

Short descriptiontext

Pre Diagnostics AS is a Norwegian diagnostics company developing CE-marked blood-based biomarker tests for early detection of Alzheimer's disease and pipeline products for Parkinson's disease and ARIA monitoring, serving pharmaceutical companies, research institutions, and hospitals via its proprietary intracellular Aβ clearance platform and Pre Neurolab service laboratory.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersOslo, Norway
HQ citystring
Oslo
HQ countrystring
Norway
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
neurodegenerative disease diagnostics, Alzheimer blood biomarker tests, immunoassay services, clinical biomarker analysis, intracellular diagnostic assays
Industry3 codes
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing
NAICS code3 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical Laboratories621511
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code2 codes
  • In Vitro & In Vivo Diagnostic Substances2835
  • Services-Medical Laboratories8071
Product category
Neurodegenerative Disease Diagnostics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Biomarker Services (Pre Neurolab)
TypeProfessional Services
Description

Pre Neurolab provides analytical biomarker services for neurodegenerative diseases, supporting research biomarker studies using advanced immunoassay platforms. Services accommodate sample sizes ranging from 50 to several thousands. Supports standard biomarker panels and custom assay development.

pre-diagnostics.com
2Pharma Clinical Research Partnerships
TypeLicensing Royalties
Description

The company is in active dialogue with pharmaceutical companies to commercialize biomarkers for clinical research, patient monitoring/screening, and diagnostics for neurodegenerative diseases.

pre-diagnostics.com
3Diagnostic Test Sales
TypeOne Time License
Description

PreADx blood test (CE-marked) for early detection of Alzheimer's disease through measurement of Aβ clearance efficiency. Additional diagnostic products in development for Alzheimer's and Parkinson's disease.

pre-diagnostics.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 4 records shown
1Pre Neurolab
Description

Service laboratory providing analytical biomarker services for neurodegenerative diseases using advanced immunoassay platforms. Supports studies from 50 to several thousand samples.

pre-diagnostics.com
+3 more records
Core offering1 text field

Pre Diagnostics develops and commercializes proprietary blood-based biomarker diagnostics for neurodegenerative diseases. Its core offering is the PreADx CE-marked in-vitro diagnostic blood test, which uses an intracellular monocyte-based two-step platform with proprietary monoclonal antibodies to detect early Alzheimer's disease by measuring ongoing Aβ clearance. The company also operates Pre Neurolab, a service laboratory providing analytical biomarker services using advanced immunoassay platforms (MSD and Kleeya) supporting neurodegenerative disease research studies of 50 to several thousand samples.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Reduces Alzheimer's disease diagnosis time from years to months through early detection
+2 more records
Product overview1 text field

Pre Diagnostics offers a portfolio of biomarker-based diagnostic products for neurodegenerative diseases centered on its proprietary Two-Step Platform Technology. The core platform enables measurement of Aβ clearance efficiency through monocyte isolation and proprietary antibody detection. Key products include PreADx (CE-marked Alzheimer's diagnostic), Plasma Aβx-34 CE-Marked Biomarker (ARIA monitoring), BloodCellDx-AD (ARIA risk prediction, in development), and a Parkinson's disease blood test (in development). The company also operates Pre Neurolab, a dedicated service laboratory offering analytical biomarker services using advanced immunoassay platforms including MSD and Kleeya, supporting studies from 50 to several thousand samples. The FluiDx-AD consortium project is developing additional saliva and blood-based diagnostic tests.

Product and service3 records
1PreADx
CategoryDiagnostic Test (CE-marked IVD)
Description

First CE-marked in-vitro diagnostic blood test using intracellular peptide quantitation for accurate Alzheimer's disease diagnosis. Measures ongoing clearance of beta amyloid (Abeta) via a two-step process involving monocyte isolation and proprietary monoclonal antibody detection.

2Pre Neurolab
CategoryLaboratory Services
Description

Specialized service laboratory providing analytical biomarker services for neurodegenerative diseases using advanced immunoassay platforms (MSD digital immunoassay and Kleeya). Supports studies ranging from 50 to several thousand samples with ISO 13485-compliant SOP-based analytical methods.

3Plasma Aβx-34 CE-Marked Biomarker
CategoryBiomarker Assay (CE-marked)
Description

CE-marked plasma biomarker assay used to monitor Amyloid-Related Imaging Abnormalities (ARIA) during the course of Alzheimer's disease immunotherapy treatment.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Partnership5 partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading the FluiDx-AD consortium. Pre Diagnostics AS is a key partner in this Horizon Europe-funded initiative bringing together experts across Europe to advance precision diagnostics for Alzheimer's disease. The consortium includes leading hospitals, patient organisations, and SMEs.

2FluiDx-AD Consortium Partners
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Horizon Europe-funded initiative including leading hospitals, patient organisations, and SMEs across Europe. Consortium aims to improve early diagnosis and management of Alzheimer's disease through development of three complementary diagnostic tests based on saliva, plasma, and whole blood.

pre-diagnostics.com
Strategic tierMinorTypeGTM or Marketing Partner
Description

Helped find and adapt the FluiDx-AD project to the RIA programme within Horizon Europe.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Helped find and adapt the FluiDx-AD project to the RIA programme within Horizon Europe.

Strategic tierMinorTypeGTM or Marketing Partner
Description

Contributed to creating a broader EU funding strategy for the FluiDx-AD project.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

ALZpath develops the ALZpathDx pTau217 blood test for Alzheimer's detection and is a direct peer in the blood-based AD biomarker space. Both companies target the same clinical and pharma trial customer base with non-invasive AD diagnostics, though ALZpath uses a plasma pTau mechanism versus Pre Diagnostics' intracellular approach.

TypeBroad incumbent
Description

Quanterix provides the Simoa ultra-sensitive single-molecule array immunoassay platform used widely in neurodegenerative disease biomarker research, including by pharma for AD clinical trials. It is a broad incumbent whose technology underpins competing blood-based AD assays, and overlaps with Pre Diagnostics' immunoassay-based biomarker service offerings.

TypeDirect peer
Description

Fujirebio is a specialty IVD company focused on neurodegenerative disease diagnostics, including CSF and blood-based assays for Alzheimer's (Lumipulse). It is a direct peer competing for the same clinical laboratory customers and pharma clinical trial biomarker contracts in the AD diagnostic category.

4ADx NeuroSciences
TypeDirect peer
Description

ADx NeuroSciences is a Belgian biotech developing proprietary antibodies and biomarker assays for neurodegenerative diseases including Alzheimer's. It is a direct peer in the AD biomarker development space and a potential collaborator or competitor for pharma pharma pharma trial biomarker supply.

TypeDirect peer
Description

C2N Diagnostics is the most direct comparable peer, offering the PrecivityAD blood test for Alzheimer's disease detection using mass spectrometry-based Aβ42/40 ratio measurement. Both companies compete for pharma clinical trial biomarker budgets and clinical AD diagnostic adoption in the same blood-based AD biomarker category.

TypeBroad incumbent
Description

Roche Diagnostics offers the Elecsys Amyloid plasma panel (pTau181, Aβ42/40) for AD diagnostics and is the largest commercial IVD competitor in the blood-based AD space. As a broad incumbent with global commercial reach and FDA-cleared assays, Roche represents both a competitive threat and potential partnership channel for Pre Diagnostics.

TypeBroad incumbent
Description

Bio-Techne provides proteomic biomarker tools, antibodies, and assay kits used in neurodegenerative disease research, including the ProteinSimple platform. It is a broad incumbent in life science tools whose products and services overlap with Pre Neurolab's immunoassay service offerings and whose research reagents compete with Pre Diagnostics' proprietary antibodies.

TypeBroad incumbent
Description

Euroimmun, now part of Revvity/PerkinElmer, is a major specialty diagnostics company offering a broad portfolio of immunoassays for neurodegenerative and autoimmune diseases. As a broad incumbent with established pharma and clinical lab relationships, it overlaps with Pre Diagnostics' immunoassay-based biomarker service business.

TypeBroad incumbent
Description

Sysmex is a major in-vitro diagnostics company with expanding presence in neurodegenerative disease biomarkers, including partnerships for blood-based AD assays in Japan and Europe. It is a broad incumbent whose established global clinical lab distribution network represents both competition and a potential commercialization channel for Pre Diagnostics.

TypeEmerging player
Description

Biogen is a major Alzheimer's therapeutics company (lecanemab co-developer with Eisai) that is increasingly developing in-house and partnered companion diagnostics for AD, including blood-based screening tools. It is an emerging player in the AD biomarker space with strong pharma trial pull-through demand that aligns with Pre Diagnostics' pharma partnership target customer.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses1 record

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pre Diagnostics

Neurodegenerative Disease Diagnosticspre-diagnostics.com

Pre Diagnostics AS is a Norwegian diagnostics company developing CE-marked blood-based biomarker tests for early detection of Alzheimer's disease and pipeline products for Parkinson's disease and ARIA monitoring, serving pharmaceutical companies, research institutions, and hospitals via its proprietary intracellular Aβ clearance platform and Pre Neurolab service laboratory.

What Pre Diagnostics does

Pre Diagnostics AS is a privately held Norwegian diagnostic company founded in 2013 in Oslo, developing biomarker-based blood tests for early detection and management of neurodegenerative diseases, primarily Alzheimer's and Parkinson's. The company's core technology is a proprietary two-step platform that measures beta-amyloid (Aβ) clearance efficiency inside blood monocytes using positive isolation with paramagnetic beads followed by proprietary monoclonal antibody detection of specific Aβ cut-point fragments (aa-34, 20-aa, aa-40/42). Its lead commercial product, PreADx, is the first CE-marked in-vitro diagnostic blood test using intracellular peptide quantitation for early Alzheimer's disease detection, and it has also CE-marked the Plasma Aβx-34 biomarker for monitoring Amyloid-Related Imaging Abnormalities (ARIA) during anti-amyloid immunotherapy, with BloodCellDx-AD in development for ARIA risk prediction.

Pre Diagnostics operates three revenue streams: (i) professional biomarker services through its wholly owned subsidiary Pre Neurolab, a service laboratory established in 2022 and expanded in February 2026 with MSD and Kleeya immunoassay platforms supporting studies from 50 to several thousand samples; (ii) licensing and royalty arrangements under active dialogue with pharmaceutical companies for clinical research, patient monitoring, and diagnostic applications; and (iii) one-time license sales of CE-marked diagnostic tests. The company sells primarily to pharmaceutical companies conducting neurodegenerative clinical trials and to academic research institutions and hospitals, with secondary outreach to clinicians via the PreADx test. The commercial footprint is currently European, anchored by participation in the €7.7 million Horizon Europe-funded FluiDx-AD consortium led by Oslo University Hospital, alongside the Norwegian Research Council-funded Parkinson's program. The company is small (1-10 employees), ISO 13485 certified, and has historically been financed primarily through EU and Norwegian research grants rather than commercial revenue.

Pre Diagnostics firmographics

Firmographics
Name
Pre Diagnostics
Legal name
Pre Diagnostics AS
Website
https://pre-diagnostics.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
Pre Diagnostics AS is a Norwegian diagnostics company developing CE-marked blood-based biomarker tests for early detection of Alzheimer's disease and pipeline products for Parkinson's disease and ARIA monitoring, serving pharmaceutical companies, research institutions, and hospitals via its proprietary intracellular Aβ clearance platform and Pre Neurolab service laboratory.
Ownership category
akta.pro rank

Pre Diagnostics industry classification

Industry
Product category
Neurodegenerative Disease Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical Laboratories (621511), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
In Vitro & In Vivo Diagnostic Substances (2835), Services-Medical Laboratories (8071)
akta.pro industry
PRIMARYHLAGAEAB
Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Central Labs & Clinical Diagnostics Services (Trial Support)
SECONDARYHLAAAMAC
Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays)
Healthcare & Life Sciences/Biotechnology & Biologics/Biomarkers and Companion Diagnostics
SECONDARYHLAGADAG
Proteomics & Biomarker Analytical Testing

Keywords

  • Neurodegenerative disease diagnostics
  • Alzheimer blood biomarker tests
  • Immunoassay services
  • Clinical biomarker analysis
  • Intracellular diagnostic assays

Where Pre Diagnostics is headquartered

Location

Headquarters

HQ city
Oslo
HQ country
Norway
HQ region
Europe

Offices2 records

Markets served

Pre Diagnostics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Biomarker Services (Pre Neurolab): Pre Neurolab provides analytical biomarker services for neurodegenerative diseases, supporting research biomarker studies using advanced immunoassay platforms. Services accommodate sample sizes ranging from 50 to several thousands. Supports standard biomarker panels and custom assay development.
  2. Pharma Clinical Research Partnerships: The company is in active dialogue with pharmaceutical companies to commercialize biomarkers for clinical research, patient monitoring/screening, and diagnostics for neurodegenerative diseases.
  3. Diagnostic Test Sales: PreADx blood test (CE-marked) for early detection of Alzheimer's disease through measurement of Aβ clearance efficiency. Additional diagnostic products in development for Alzheimer's and Parkinson's disease.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Pre Diagnostics product offering

Product offering

Core offering

Pre Diagnostics develops and commercializes proprietary blood-based biomarker diagnostics for neurodegenerative diseases. Its core offering is the PreADx CE-marked in-vitro diagnostic blood test, which uses an intracellular monocyte-based two-step platform with proprietary monoclonal antibodies to detect early Alzheimer's disease by measuring ongoing Aβ clearance. The company also operates Pre Neurolab, a service laboratory providing analytical biomarker services using advanced immunoassay platforms (MSD and Kleeya) supporting neurodegenerative disease research studies of 50 to several thousand samples.

Product overview

Pre Diagnostics offers a portfolio of biomarker-based diagnostic products for neurodegenerative diseases centered on its proprietary Two-Step Platform Technology. The core platform enables measurement of Aβ clearance efficiency through monocyte isolation and proprietary antibody detection. Key products include PreADx (CE-marked Alzheimer's diagnostic), Plasma Aβx-34 CE-Marked Biomarker (ARIA monitoring), BloodCellDx-AD (ARIA risk prediction, in development), and a Parkinson's disease blood test (in development). The company also operates Pre Neurolab, a dedicated service laboratory offering analytical biomarker services using advanced immunoassay platforms including MSD and Kleeya, supporting studies from 50 to several thousand samples. The FluiDx-AD consortium project is developing additional saliva and blood-based diagnostic tests.

Differentiator

Problem solved

Functional benefit

Brands

  • Pre Neurolab: Service laboratory providing analytical biomarker services for neurodegenerative diseases using advanced immunoassay platforms. Supports studies from 50 to several thousand samples.
  • PreADx
  • BloodCellDx-AD
  • Plasma Aβx-34

Products and services

  • PreADx First CE-marked in-vitro diagnostic blood test using intracellular peptide quantitation for accurate Alzheimer's disease diagnosis. Measures ongoing clearance of beta amyloid (Abeta) via a two-step process involving monocyte isolation and proprietary monoclonal antibody detection.
  • Pre Neurolab Specialized service laboratory providing analytical biomarker services for neurodegenerative diseases using advanced immunoassay platforms (MSD digital immunoassay and Kleeya). Supports studies ranging from 50 to several thousand samples with ISO 13485-compliant SOP-based analytical methods.
  • Plasma Aβx-34 CE-Marked Biomarker CE-marked plasma biomarker assay used to monitor Amyloid-Related Imaging Abnormalities (ARIA) during the course of Alzheimer's disease immunotherapy treatment.

Quantifiable outcome

  • Reduces Alzheimer's disease diagnosis time from years to months through early detection
  • +2 more outcomes

Companies that use Pre Diagnostics

Customer profile

Segments3 records

Ideal customer profiles3 records

Pre Diagnostics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Pre Diagnostics partnerships and signals

Strategic signal

Partnerships

Five partnerships are on record, tiered core and minor.

  • Oslo University HospitalcoreStrategic or Co-development PartnerLeading the FluiDx-AD consortium. Pre Diagnostics AS is a key partner in this Horizon Europe-funded initiative bringing together experts across Europe to advance precision diagnostics for Alzheimer's disease. The consortium includes leading hospitals, patient organisations, and SMEs.
  • FluiDx-AD Consortium PartnerscoreStrategic or Co-development PartnerHorizon Europe-funded initiative including leading hospitals, patient organisations, and SMEs across Europe. Consortium aims to improve early diagnosis and management of Alzheimer's disease through development of three complementary diagnostic tests based on saliva, plasma, and whole blood.
  • Norway Health TechminorGTM or Marketing PartnerHelped find and adapt the FluiDx-AD project to the RIA programme within Horizon Europe.
  • InnovaytminorGTM or Marketing PartnerHelped find and adapt the FluiDx-AD project to the RIA programme within Horizon Europe.
  • Innovation NorwayminorGTM or Marketing PartnerContributed to creating a broader EU funding strategy for the FluiDx-AD project.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Pre Diagnostics competitors and assessment

Company assessment

Direct peers

  • ALZpath: ALZpath develops the ALZpathDx pTau217 blood test for Alzheimer's detection and is a direct peer in the blood-based AD biomarker space. Both companies target the same clinical and pharma trial customer base with non-invasive AD diagnostics, though ALZpath uses a plasma pTau mechanism versus Pre Diagnostics' intracellular approach.
  • Fujirebio: Fujirebio is a specialty IVD company focused on neurodegenerative disease diagnostics, including CSF and blood-based assays for Alzheimer's (Lumipulse). It is a direct peer competing for the same clinical laboratory customers and pharma clinical trial biomarker contracts in the AD diagnostic category.
  • ADx NeuroSciences: ADx NeuroSciences is a Belgian biotech developing proprietary antibodies and biomarker assays for neurodegenerative diseases including Alzheimer's. It is a direct peer in the AD biomarker development space and a potential collaborator or competitor for pharma pharma pharma trial biomarker supply.
  • C2N Diagnostics: C2N Diagnostics is the most direct comparable peer, offering the PrecivityAD blood test for Alzheimer's disease detection using mass spectrometry-based Aβ42/40 ratio measurement. Both companies compete for pharma clinical trial biomarker budgets and clinical AD diagnostic adoption in the same blood-based AD biomarker category.

Broad incumbents

  • Quanterix: Quanterix provides the Simoa ultra-sensitive single-molecule array immunoassay platform used widely in neurodegenerative disease biomarker research, including by pharma for AD clinical trials. It is a broad incumbent whose technology underpins competing blood-based AD assays, and overlaps with Pre Diagnostics' immunoassay-based biomarker service offerings.
  • Roche Diagnostics: Roche Diagnostics offers the Elecsys Amyloid plasma panel (pTau181, Aβ42/40) for AD diagnostics and is the largest commercial IVD competitor in the blood-based AD space. As a broad incumbent with global commercial reach and FDA-cleared assays, Roche represents both a competitive threat and potential partnership channel for Pre Diagnostics.
  • Bio-Techne: Bio-Techne provides proteomic biomarker tools, antibodies, and assay kits used in neurodegenerative disease research, including the ProteinSimple platform. It is a broad incumbent in life science tools whose products and services overlap with Pre Neurolab's immunoassay service offerings and whose research reagents compete with Pre Diagnostics' proprietary antibodies.
  • Euroimmun (PerkinElmer): Euroimmun, now part of Revvity/PerkinElmer, is a major specialty diagnostics company offering a broad portfolio of immunoassays for neurodegenerative and autoimmune diseases. As a broad incumbent with established pharma and clinical lab relationships, it overlaps with Pre Diagnostics' immunoassay-based biomarker service business.
  • Sysmex: Sysmex is a major in-vitro diagnostics company with expanding presence in neurodegenerative disease biomarkers, including partnerships for blood-based AD assays in Japan and Europe. It is a broad incumbent whose established global clinical lab distribution network represents both competition and a potential commercialization channel for Pre Diagnostics.

Emerging players

  • Biogen: Biogen is a major Alzheimer's therapeutics company (lecanemab co-developer with Eisai) that is increasingly developing in-house and partnered companion diagnostics for AD, including blood-based screening tools. It is an emerging player in the AD biomarker space with strong pharma trial pull-through demand that aligns with Pre Diagnostics' pharma partnership target customer.

Market position

Strengths1 record

Weaknesses1 record

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Pre Diagnostics social profiles

Digital presence

Pre Diagnostics compliance and trust

Trust signal

Compliance1 record

Pre Diagnostics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pre Diagnostics leadership team

Management profile

Number of profiles

Profiles4 records

Pre Diagnostics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Pre Diagnostics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pre Diagnostics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pre Diagnostics

What does Pre Diagnostics do?

Pre Diagnostics develops and commercializes proprietary blood-based biomarker diagnostics for neurodegenerative diseases. Its core offering is the PreADx CE-marked in-vitro diagnostic blood test, which uses an intracellular monocyte-based two-step platform with proprietary monoclonal antibodies to detect early Alzheimer's disease by measuring ongoing Aβ clearance. The company also operates Pre Neurolab, a service laboratory providing analytical biomarker services using advanced immunoassay platforms (MSD and Kleeya) supporting neurodegenerative disease research studies of 50 to several thousand samples.

Is Pre Diagnostics a public or private company?

Pre Diagnostics is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Pre Diagnostics founded?

Pre Diagnostics was founded in 2013. It employs 11 to 50 people.

Where is Pre Diagnostics based?

Pre Diagnostics is headquartered in Oslo, Norway, in the Europe region.

How does Pre Diagnostics make money?

Three revenue lines are on record. Biomarker Services (Pre Neurolab) is the primary driver. The others are pharma Clinical Research Partnerships and diagnostic Test Sales.

Who are Pre Diagnostics's main competitors?

Direct peers on record are ALZpath, Fujirebio, ADx NeuroSciences and C2N Diagnostics. Broad incumbents are Quanterix, Roche Diagnostics, Bio-Techne, Euroimmun (PerkinElmer) and Sysmex. Biogen is listed as an emerging player.

Does Pre Diagnostics have an API?

No public API is recorded for Pre Diagnostics.

What industry is Pre Diagnostics in?

Pre Diagnostics's product category is Neurodegenerative Disease Diagnostics. Its primary akta.pro industry code is HLAGAEAB, Specialty & Biomarker Laboratory Services (Immunoassays/Flow/Cytometry), with a secondary code of HLAAAMAC, Clinical Biomarker Testing Services (central labs, trial enrollment/monitoring assays). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales